Travoprost Remains a Reliable and Effective Glaucoma Treatment

Travoprost Remains a Reliable and Effective Glaucoma Treatment


With a 5.6 billion dollar market worldwide for treating glaucoma, research and development of new treatments are both needed and inevitable. Travoprost, currently a safe and efficacious therapy, continues to be a reliable treatment for the onslaught of patients around the globe suffering from glaucoma. With no cure for this debilitating eye disease, glaucoma is projected to affect over 4 million Americans by the year 2030. Preventing the eventuality of blindness for patients who are untreated for glaucoma is key, and the use of Travoprost is an effective preventative therapy.

Travoprost is a synthetic prostaglandin F analogue which works by draining fluid in the eye, thus reducing eye pressure. This opthamolic solution is prescribed to treat and prevent several types of glaucoma, as well as conditions which cause high pressure in the eyes. Travoprost is supplied as the brand name Travatan and Travatan Z, which is marketed by Alcon Laboratories. A ndverse effects are extremely uncommon, with common side effects being reported being minor eye discomfort and stinging of the eyes after drop administration. A small number of patients who have used Travoprost for a period of time have reported a darkening of the iris in their eye, which seems to affect people who receive Travoprost for one eye only. These pigment changes can be permanent, but they are not detrimental to the health of the eye.

As the second leading cause of blindness worldwide the development of novel treatments to combat glaucoma are necessary. Revenues for Alcon’s glaucoma treatments exceeded 1.3 billion dollars in 2014. LGM Pharma can assist clients as a supplier/distributor of the API Travoprost, CAS # 157283-68-6 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service